Similar articles

• Second-line FOLFOX is not the standard of care for all patients with advanced biliary tract cancer-a commentary from the Young International Society of Geriatric Oncology.

  Liposits G, Arora SP, Battisti NML, Soto-Perez-de-Celis E, Loh KP, Williams GR. Liposits G, et al. Ann Oncol. 2023 Jun;34(6):555-556. doi: 10.1016/j.annonc.2023.02.007. Epub 2023 Feb 21. Ann Oncol. 2023. PMID: 36813114 No abstract available.
• Fluoropyrimidine-based doublet chemotherapy as second-line treatment for advanced biliary tract cancer: a meta-analysis of ABC-06 and NIFTY.

  Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, Palmiotti G. Rizzo A, et al. Expert Rev Gastroenterol Hepatol. 2022 Mar;16(3):273-278. doi: 10.1080/17474124.2022.2047651. Epub 2022 Mar 2. Expert Rev Gastroenterol Hepatol. 2022. PMID: 35220866
• TOPAZ-1: a new standard of care for advanced biliary tract cancers?

  Ebia MI, Sankar K, Osipov A, Hendifar AE, Gong J. Ebia MI, et al. Immunotherapy. 2023 May;15(7):473-476. doi: 10.2217/imt-2022-0269. Epub 2023 Mar 23. Immunotherapy. 2023. PMID: 36950948 No abstract available.
• Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data.

  Ying J, Chen J. Ying J, et al. Crit Rev Oncol Hematol. 2019 Jul;139:134-142. doi: 10.1016/j.critrevonc.2019.01.001. Epub 2019 Jan 4. Crit Rev Oncol Hematol. 2019. PMID: 30979533 Review.
• Second-line therapy in advanced biliary tract cancer: what should be the standard?

  Cereda S, Belli C, Rognone A, Mazza E, Reni M. Cereda S, et al. Crit Rev Oncol Hematol. 2013 Nov;88(2):368-74. doi: 10.1016/j.critrevonc.2013.05.010. Epub 2013 Jun 17. Crit Rev Oncol Hematol. 2013. PMID: 23786845 Review.